Pathways driving the endocytosis of mutant and wild-type EGFR in cancer

Oncoscience

Volumn 1, Issue 8, 2014, Pages 504-512

  Hampton, Kaia K ^a   Craven, Rolf J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Endocytosis; Kinase; Receptor; Signaling; Therapeutics

Indexed keywords

EID: 84928716915     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.67     Document Type: Article

References (92)

1. Lemmon MA and Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010; 141: 1117-1134.
2. Hynes NE and Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5: 341-354.
3. Langdon WY, Hartley JW, Klinken SP, Ruscetti SK and Morse HC, 3rd. v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas. Proc Natl Acad Sci U S A. 1989; 86: 1168-1172.
4. Schmidt MH and Dikic I. The Cbl interactome and its functions. Nat Rev Mol Cell Biol. 2005; 6: 907-918.
5. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B and Yarden Y. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 1998; 12: 3663-3674.
6. Tomas A, Futter CE and Eden ER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol. 2014; 24: 26-34.
7. Anastasi S, Sala G, Huiping C, Caprini E, Russo G, Iacovelli S, Lucini F, Ingvarsson S and Segatto O. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene. 2005; 24: 4540-4548.
8. Xu D, Makkinje A and Kyriakis JM. Gene 33 is an endogenous inhibitor of epidermal growth factor (EGF) receptor signaling and mediates dexamethasone-induced suppression of EGF function. J Biol Chem. 2005; 280: 2924-2933.
9. Hackel PO, Gishizky M and Ullrich A. Mig-6 is a negative regulator of the epidermal growth factor receptor signal. Biol Chem. 2001; 382: 1649-1662.
10. Anastasi S, Fiorentino L, Fiorini M, Fraioli R, Sala G, Castellani L, Alema S, Alimandi M and Segatto O. Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene. 2003; 22: 4221-4234.
11. Anastasi S, Baietti MF, Frosi Y, Alema S and Segatto O. The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity. Oncogene. 2007; 26: 7833-7846.
12. Zhang X, Pickin KA, Bose R, Jura N, Cole PA and Kuriyan J. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature. 2007; 450(7170): 741-744.
13. Segatto O, Anastasi S and Alema S. Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors. J Cell Sci. 2011; 124(Pt 11): 1785-1793.
14. Ferby I, Reschke M, Kudlacek O, Knyazev P, Pante G, Amann K, Sommergruber W, Kraut N, Ullrich A, Fassler R and Klein R. Mig6 is a negative regulator of EGF receptormediated skin morphogenesis and tumor formation. Nature Med. 2006; 12: 568-573.
15. Hopkins S, Linderoth E, Hantschel O, Suarez-Henriques P, Pilia G, Kendrick H, Smalley MJ, Superti-Furga G and Ferby I. Mig6 is a sensor of EGF receptor inactivation that directly activates c-Abl to induce apoptosis during epithelial homeostasis. Dev Cell. 2012; 23: 547-559.
16. Tsai KK and Yuan ZM. c-Abl stabilizes p73 by a phosphorylation-augmented interaction. Cancer Res. 2003; 63: 3418-3424.
17. Wang JY. Nucleo-cytoplasmic communication in apoptotic response to genotoxic and inflammatory stress. Cell Res. 2005; 15: 43-48.
18. Ganguly SS and Plattner R. Activation of abl family kinases in solid tumors. Genes & cancer. 2012; 3(5-6): 414-425.
19. Ying H, Zheng H, Scott K, Wiedemeyer R, Yan H, Lim C, Huang J, Dhakal S, Ivanova E, Xiao Y, Zhang H, Hu J, Stommel JM, Lee MA, Chen AJ, Paik JH, et al. Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proc Natl Acad Sci U S A. 2010; 107: 6912-6917.
20. Frosi Y, Anastasi S, Ballaro C, Varsano G, Castellani L, Maspero E, Polo S, Alema S and Segatto O. A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation. J Cell Biol. 2010; 189: 557-571.
21. Walsh AM and Lazzara MJ. Differential parsing of EGFR endocytic flux among parallel internalization pathways in lung cancer cells with EGFR-activating mutations. Integr Biol (Camb). 2014; 6: 312-323.
22. Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S and Di Fiore PP. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell. 2008; 15: 209-219.
23. Wang Z, Raines LL, Hooy RM, Roberson H, Leahy DJ and Cole PA. Tyrosine phosphorylation of mig6 reduces its inhibition of the epidermal growth factor receptor. ACS Chem Biol. 2013; 8: 2372-2376.
24. Martin NP, Mohney RP, Dunn S, Das M, Scappini E and O'Bryan JP. Intersectin regulates epidermal growth factor receptor endocytosis, ubiquitylation, and signaling. Mol Pharmacol. 2006; 70: 1643-1653.
25. Hunter MP, Russo A and O'Bryan JP. Emerging Roles for Intersectin (ITSN) in Regulating Signaling and Disease Pathways. Int J Mol Sci. 2013; 14: 7829-7852.
26. Okur MN, Russo A and O'Bryan JP. Receptor tyrosine kinase ubiquitylation involves the dynamic regulation of Cbl-Spry2 by intersectin 1 and the Shp2 tyrosine phosphatase. Mol Cell Biol. 2014; 34: 271-279.
27. Pawson T and Gish GD. SH2 and SH3 domains: from structure to function. Cell. 1992; 71: 359-362.
28. Wong ES, Lim J, Low BC, Chen Q and Guy GR. Evidence for direct interaction between Sprouty and Cbl. J Biol Chem. 2001; 276: 5866-5875.
29. Hanafusa H, Torii S, Yasunaga T and Nishida E. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat Cell Biol. 2002; 4: 850-858.
30. Hanafusa H, Torii S, Yasunaga T, Matsumoto K and Nishida E. Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty. J Biol Chem. 2004; 279: 22992-22995.
31. Guy GR, Jackson RA, Yusoff P and Chow SY. Sprouty proteins: modified modulators, matchmakers or missing links? J Endocrinol. 2009; 203: 191-202.
32. Rohe HJ, Ahmed IS, Twist KE and Craven RJ. PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharmacol Ther. 2009; 121: 14-19.
33. Ahmed IS, Rohe HJ, Twist KE, Mattingly MN and Craven RJ. Progesterone receptor membrane component 1 (Pgrmc1): a heme-1 domain protein that promotes tumorigenesis and is inhibited by a small molecule. J Pharmacol Exp Ther. 2010; 333: 564-573.
34. Xu J, Zeng C, Chu W, Pan F, Rothfuss JM, Zhang F, Tu Z, Zhou D, Zeng D, Vangveravong S, Johnston F, Spitzer D, Chang KC, Hotchkiss RS, Hawkins WG, Wheeler KT, et al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun. 2011; 2: 380.
35. Meyer C, Schmieding K, Falkenstein E and Wehling M. Are high-affinity progesterone binding site(s) from porcine liver microsomes members of the sigma receptor family? Eur J Pharmacol. 1998; 347(2-3): 293-299.
36. Liu L, Wang J, Zhao L, Nilsen J, McClure K, Wong K and Brinton RD. Progesterone increases rat neural progenitor cell cycle gene expression and proliferation via extracellularly regulated kinase and progesterone receptor membrane components 1 and 2. Endocrinology. 2009; 150: 3186-3196.
37. Peluso JJ, Pappalardo A, Losel R and Wehling M. Progesterone membrane receptor component 1 expression in the immature rat ovary and its role in mediating progesterone's antiapoptotic action. Endocrinology. 2006; 147: 3133-3140.
38. Peluso JJ, Romak J and Liu X. Progesterone receptor membrane component-1 (PGRMC1) is the mediator of progesterone's antiapoptotic action in spontaneously immortalized granulosa cells as revealed by PGRMC1 small interfering ribonucleic acid treatment and functional analysis of PGRMC1 mutations. Endocrinology. 2008; 149: 534-543.
39. Thomas P, Pang Y and Dong J. Enhancement of cell surface expression and receptor functions of membrane progestin receptor alpha (mPRalpha) by progesterone receptor membrane component 1 (PGRMC1): evidence for a role of PGRMC1 as an adaptor protein for steroid receptors. Endocrinology. 2014; 155: 1107-1119.
40. Ahmed IS, Rohe HJ, Twist KE and Craven RJ. Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity. J Biol Chem. 2010; 285: 24775-24782.
41. Nolte I, Jeckel D, Wieland FT and Sohn K. Localization and topology of ratp28, a member of a novel family of putative steroid-binding proteins. Biochim Biophys Acta. 2000; 1543: 123-130.
42. Meyer C, Schmid R, Scriba PC and Wehling M. Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes. Eur J Biochem. 1996; 239: 726-731.
43. Krebs CJ, Jarvis ED, Chan J, Lydon JP, Ogawa S and Pfaff DW. A membrane-associated progesterone-binding protein, 25-Dx, is regulated by progesterone in brain regions involved in female reproductive behaviors. Proc Natl Acad Sci U S A. 2000; 97: 12816-12821.
44. Su C, Cunningham RL, Rybalchenko N and Singh M. Progesterone increases the release of brain-derived neurotrophic factor from glia via progesterone receptor membrane component 1 (Pgrmc1)-dependent ERK5 signaling. Endocrinology. 2012; 153: 4389-4400.
45. Labombarda F, Gonzalez SL, Deniselle MC, Vinson GP, Schumacher M, De Nicola AF and Guennoun R. Effects of injury and progesterone treatment on progesterone receptor and progesterone binding protein 25-Dx expression in the rat spinal cord. J Neurochem. 2003; 87: 902-913.
46. Bali N, Arimoto JM, Iwata N, Lin SW, Zhao L, Brinton RD, Morgan TE and Finch CE. Differential responses of progesterone receptor membrane component-1 (Pgrmc1) and the classical progesterone receptor (Pgr) to 17betaestradiol and progesterone in hippocampal subregions that support synaptic remodeling and neurogenesis. Endocrinology. 2012; 153: 759-769.
47. Neubauer H, Clare SE, Wozny W, Schwall GP, Poznanovic S, Stegmann W, Vogel U, Sotlar K, Wallwiener D, Kurek R, Fehm T and Cahill MA. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res. 2008; 10: R85.
48. Hand RA and Craven RJ. Hpr6.6 protein mediates cell death from oxidative damage in MCF-7 human breast cancer cells. J Cell Biochem. 2003; 90: 534-547.
49. Mir SU, Jin L and Craven RJ. Neutrophil gelatinaseassociated lipocalin (NGAL) expression dependent on the tumor-associated sigma-2 receptor S2RPgrmc1. J Biol Chem. 2012.
50. Bolignano D, Donato V, Lacquaniti A, Fazio MR, Bono C, Coppolino G and Buemi M. Neutrophil gelatinaseassociated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett. 2010; 288: 10-16.
51. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, Greenbaum DC, Hager JH, Bogyo M and Hanahan D. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell. 2004; 5: 443-453.
52. Yoshitani N, Satou K, Saito K, Suzuki S, Hatanaka H, Seki M, Shinozaki K, Hirota H and Yokoyama S. A structurebased strategy for discovery of small ligands binding to functionally unknown proteins: combination of in silico screening and surface plasmon resonance measurements. Proteomics. 2005; 5: 1472-1480.
53. Ostenfeld MS, Fehrenbacher N, Hoyer-Hansen M, Thomsen C, Farkas T and Jaattela M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res. 2005; 65: 8975-8983.
54. Ghelardini C, Galeotti N, Gualtieri F, Bellucci C, Manetti D, Giotti A, Malmberg-Aiello P, Galli A and Bartolini A. Antinociceptive profile of 3-alpha-tropanyl 2-(4-Clphenoxy) butyrate (SM-21) [corrected]: a novel analgesic with a presynaptic cholinergic mechanism of action. J Pharmacol Exp Ther. 1997; 282: 430-439.
55. Berardi F, Ferorelli S, Abate C, Colabufo NA, Contino M, Perrone R and Tortorella V. 4-(tetralin-1-yl)-and 4-(naphthalen-1-yl)alkyl derivatives of 1-cyclohexylpiperazine as sigma receptor ligands with agonist sigma2 activity. J Med Chem. 2004; 47: 2308-2317.
56. Zeng C, Vangveravong S, Xu J, Chang KC, Hotchkiss RS, Wheeler KT, Shen D, Zhuang ZP, Kung HF and Mach RH. Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Cancer Res. 2007; 67: 6708-6716.
57. Crawford KW and Bowen WD. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 2002; 62: 313-322.
58. Kashiwagi H, McDunn JE, Simon PO, Jr., Goedegebuure PS, Xu J, Jones L, Chang K, Johnston F, Trinkaus K, Hotchkiss RS, Mach RH and Hawkins WG. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer. 2007; 6: 48.
59. Bromann PA, Korkaya H and Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene. 2004; 23: 7957-7968.
60. Boggon TJ and Eck MJ. Structure and regulation of Src family kinases. Oncogene. 2004; 23: 7918-7927.
61. Serfas MS and Tyner AL. Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases. Oncology Res. 2003; 13(6-10): 409-419.
62. Cance WG, Craven RJ, Bergman M, Xu L, Alitalo K and Liu ET. Rak, a novel nuclear tyrosine kinase expressed in epithelial cells. Cell Growth Differ. 1994; 5: 1347-1355.
63. Lee J, Wang Z, Luoh SM, Wood WI and Scadden DT. Cloning of FRK, a novel human intracellular SRC-like tyrosine kinase-encoding gene. Gene. 1994; 138: 247-251.
64. Craven RJ, Cance WG and Liu ET. The nuclear tyrosine kinase Rak associates with the retinoblastoma protein pRb. Cancer Res. 1995; 55: 3969-3972.
65. Meyer T, Xu L, Chang J, Liu ET, Craven RJ and Cance WG. Breast cancer cell line proliferation blocked by the Src-related Rak tyrosine kinase. Int J Cancer. 2003; 104: 139-146.
66. Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y, Mills GB, Meric-Bernstam F, Hennessy BT, Craven RJ and Lin SY. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell. 2009; 15: 304-314.
67. Jin L and Craven RJ. The Rak/Frk tyrosine kinase associates with and internalizes the epidermal growth factor receptor. Oncogene. 2014; 33: 326-335.
68. Li X, Lu Y, Liang K, Hsu JM, Albarracin C, Mills GB, Hung MC and Fan Z. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. Oncogene. 2012.
69. Kang SA and Lee ST. PTK6 promotes degradation of c-Cbl through PTK6-mediated phosphorylation. Biochem Biophys Res Commun. 2013; 431: 734-739.
70. Peng M, Ball-Kell SM, Franks RR, Xie H and Tyner AL. Protein tyrosine kinase 6 regulates mammary gland tumorigenesis in mouse models. Oncogenesis. 2013; 2: e81.
71. Regan Anderson TM, Peacock DL, Daniel AR, Hubbard GK, Lofgren KA, Girard BJ, Schorg A, Hoogewijs D, Wenger RH, Seagroves TN and Lange CA. Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression. Cancer Res. 2013; 73: 5810-5820.
72. Locatelli A, Lofgren KA, Daniel AR, Castro NE and Lange CA. Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression. Horm Cancer. 2012; 3: 14-25.
73. Castro NE and Lange CA. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells. Breast Cancer Res: BCR. 2010; 12: R60.
74. Ai M, Qiu S, Lu Y and Fan Z. HER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain. Cell Signal. 2013; 25: 1754-1761.
75. Ai M, Liang K, Lu Y, Qiu S and Fan Z. Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition. Cancer Biol Ther. 2013; 14: 237-245.
76. Lu X and Li Y. Drosophila Src42A is a negative regulator of RTK signaling. Dev Biol. 1999; 208: 233-243.
77. Goel RK, Miah S, Black K, Kalra N, Dai C and Lukong KE. The unique N-terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1. The FEBS journal. 2013; 280: 4539-4559.
78. Kohmura N, Yagi T, Tomooka Y, Oyanagi M, Kominami R, Takeda N, Chiba J, Ikawa Y and Aizawa S. A novel nonreceptor tyrosine kinase, Srm: cloning and targeted disruption. Mol Cell Biol. 1994; 14: 6915-6925.
79. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Janne PA, Shapiro GI, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFRtargeted therapies. Cancer Cell. 2006; 9: 485-495.
80. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England J Med. 2004; 350: 2129-2139.
81. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676): 1497-1500.
82. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M and Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101: 13306-13311.
83. Sordella R, Bell DW, Haber DA and Settleman J. Gefitinibsensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science. 2004; 305: 1163-1167.
84. Furukawa M, Nagatomo I, Kumagai T, Yamadori T, Takahashi R, Yoshimura M, Yoneda T, Takeda Y, Goya S, Matsuoka H, Kijima T, Yoshida M, Osaki T, Tachibana I, Greene MI and Kawase I. Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis. DNA and Cell Biol. 2007; 26: 178-185.
85. Chen YR, Fu YN, Lin CH, Yang ST, Hu SF, Chen YT, Tsai SF and Huang SF. Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene. 2006; 25: 1205-1215.
86. Padron D, Sato M, Shay JW, Gazdar AF, Minna JD and Roth MG. Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized. Cancer Res. 2007; 67: 7695-7702.
87. Liccardi G, Hartley JA and Hochhauser D. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res. 2011; 71: 1103-1114.
88. Grandal MV, Zandi R, Pedersen MW, Willumsen BM, van Deurs B and Poulsen HS. EGFRvIII escapes downregulation due to impaired internalization and sorting to lysosomes. Carcinogenesis. 2007; 28: 1408-1417.
89. Naruo Y, Nagashima T, Ushikoshi-Nakayama R, Saeki Y, Nakakuki T, Naka T, Tanaka H, Tsai SF and Okada-Hatakeyama M. Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity. BMC Systems Biol. 2011; 5: 29.
90. Walsh AM and Lazzara MJ. Regulation of EGFR trafficking and cell signaling by Sprouty2 and MIG6 in lung cancer cells. J Cell Sci. 2013; 126: 4339-4348.
91. Guha U, Chaerkady R, Marimuthu A, Patterson AS, Kashyap MK, Harsha HC, Sato M, Bader JS, Lash AE, Minna JD, Pandey A and Varmus HE. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci U S A. 2008; 105: 14112-14117.
92. Schmidt MH, Furnari FB, Cavenee WK and Bogler O. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc Natl Acad Sci U S A. 2003; 100: 6505-6510.